Literature DB >> 6704165

Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard.

S Somfai-Relle, K Suzukake, B P Vistica, D T Vistica.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6704165     DOI： 10.1016/0006-2952(84)90245-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  12 in total

Review 1.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Sensitization of human melanoma cells to melphalan cytotoxicity by adriamycin and carmustine.

Authors:  V Jevtović-Todorović; T M Guenthner; V Jevtorić-Todorović
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine.

Authors:  S X Skapek; A F VanDellen; D P McMahon; D G Postels; O W Griffith; D D Bigner; H S Friedman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells.

Authors:  R T Dorr; J D Liddil; M J Soble
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

5.  Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.

Authors:  S E Brooks; T T Korbut; N P Dupuis; S A Holden; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  DNA cell cycle distribution and glutathione (GSH) content according to circadian stage in bone marrow of cancer patients.

Authors:  R Smaaland; J F Abrahamsen; A M Svardal; K Lote; P M Ueland
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

7.  A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma.

Authors:  Judith G Villablanca; Samuel L Volchenboum; Hwangeui Cho; Min H Kang; Susan L Cohn; Clarke P Anderson; Araz Marachelian; Susan Groshen; Denice Tsao-Wei; Katherine K Matthay; John M Maris; Charlotte E Hasenauer; Scarlett Czarnecki; Hollie Lai; Fariba Goodarzian; Hiro Shimada; Charles Patrick Reynolds
Journal:  Pediatr Blood Cancer       Date:  2016-04-19       Impact factor: 3.167

8.  The use of 1H spin echo NMR and HPLC to confirm doxorubicin induced depletion of glutathione in the intact HeLa cell.

Authors:  M al-Kabban; I D Watson; M J Stewart; J Reglinski; W E Smith; C J Suckling
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

9.  Effects of glutathione depletion on the cytotoxicity of agents toward a human colonic tumour cell line.

Authors:  J Jordan; M d'Arcy Doherty; G M Cohen
Journal:  Br J Cancer       Date:  1987-06       Impact factor: 7.640

10.  Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma.

Authors:  S M Castellino; H S Friedman; G B Elion; E T Ong; S L Marcelli; R Page; D D Bigner; M W Dewhirst
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.